$1.28 0.0 0.0%
Last Trade - 19/04/21
| Market Cap | £8.59m |
| Enterprise Value | £8.15m |
| Revenue | £n/a |
| Position in Universe | 6329th / 6849 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.12 | 0.082 | 0.000 | 0.000 | 0.000 | 0.000 | 46.0 | -100.0% | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | May 3, 2012 |
| Public Since | October 14, 2013 |
| No. of Shareholders: | 155 |
| No. of Employees: | 6 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | |
| Exchange | Pink Sheets on Nasdaq |
| Shares in Issue | 9,388,407 |
| Free Float | (0.0%) |
| Eligible for |
×
ISAs
✓
SIPPs
|
| Address | 84 October Hill Rd Ste 11, HOLLISTON, 01746-1371, United States |
| Web | http://www.biostage.com/ |
| Phone | +1 774 2337300 |
| Contact | () |
| Auditors | RSM US LLP |
As of 19/04/21, shares in Biostage Inc are trading at $1.28, giving the company a market capitalisation of £8.59m. This share price information is delayed by 15 minutes.
Shares in Biostage Inc are currently trading at $1.28 and the price has moved by -60.62% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biostage Inc price has moved by -73.88% over the past year.
Of the analysts with advisory recommendations for Biostage Inc, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Biostage Inc is Not available. You can view the full broker recommendation list by unlocking its StockReport.
Biostage Inc is scheduled to issue upcoming financial results on the following dates:
Biostage Inc does not currently pay a dividend.
Biostage Inc does not currently pay a dividend.
Biostage Inc does not currently pay a dividend.
To buy shares in Biostage Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biostage Inc are currently trading at $1.28, giving the company a market capitalisation of £8.59m.
Here are the trading details for Biostage Inc:
Based on an overall assessment of its quality, value and momentum, Biostage Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for Biostage Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biostage Inc. Over the past six months, the relative strength of its shares against the market has been -23.31%. At the current price of $1.28, shares in Biostage Inc are trading at -27.23% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Biostage Inc.
Biostage Inc's management team is headed by:
Here are the top five shareholders of Biostage Inc based on the size of their shareholding:
